Literature DB >> 30199734

Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta.

Sara Salama1, Hazem Marouf2, M Ihab Reda3, Amal R Mansour4, Osama ELKholy2, Michael Levy5.   

Abstract

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the central nervous system that was previously thought to be a subtype of multiple sclerosis (MS). Epidemiology studies of NMOSD are rare in both Middle East and North African countries. To our knowledge, there are no such studies in Egypt. Herein, we describe a case series of NMOSD patients from North Egyptian Nile Delta region and compare them to NMOSD in other parts in the Middle East and the world.
METHODS: This is a case series study of NMOSD patients who were seen at the neuroimmunology clinic, Elhadara Hospital, University of Alexandria, Egypt, from January 2017 to January 2018. We describe their clinical, serological and radiological features.
RESULTS: Our study identified twenty Egyptian patients, all of who fulfilled the 2015 international NMOSD diagnostic criteria. Ten tested positive for AQP4 antibodies in the serum while the other ten were seronegative. The mean age at onset was 27.8 years with an average disease duration of 6.8 years. There was a strong female predominance with a ratio of 5.6:1. We identified clinical features of the cohort that differ from those reported in other worldwide studies.
INTERPRETATION: This is the first NMOSD case series in Egypt. Despite some limitation in testing and access to care, there are features of our NMOSD cases that appear to be different from other worldwide cohorts reported in the literature.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Egypt; MOG antibody disease; Neuromyelitis optica spectrum disorder; Optic neuritis; Transverse myelitis

Mesh:

Substances:

Year:  2018        PMID: 30199734      PMCID: PMC6170703          DOI: 10.1016/j.jneuroim.2018.08.014

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  31 in total

1.  An epidemiological study of neuromyelitis optica in Isfahan.

Authors:  Masoud Etemadifar; Masoumeh Dashti; Reza Vosoughi; Seyed Hossein Abtahi; Sreeram V Ramagopalan; Zahra Nasr
Journal:  Mult Scler       Date:  2014-06-02       Impact factor: 6.312

2.  Worldwide prevalence of neuromyelitis optica spectrum disorders.

Authors:  Masahiro Mori; Satoshi Kuwabara; Friedemann Paul
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-02-07       Impact factor: 10.154

3.  Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?

Authors:  Jonathan James Downer; Maria Isabel Leite; Ranjana Carter; Jacqueline Palace; Wilhelm Küker; Gerardine Quaghebeur
Journal:  Neuroradiology       Date:  2011-05-07       Impact factor: 2.804

4.  Long-term follow-up of neuromyelitis optica with a pediatric onset.

Authors:  N Collongues; R Marignier; H Zéphir; C Papeix; B Fontaine; F Blanc; D Rodriguez; M Fleury; S Vukusic; J Pelletier; B Audoin; E Thouvenot; W Camu; B Barroso; A Ruet; B Brochet; P Vermersch; C Confavreux; J de Seze
Journal:  Neurology       Date:  2010-09-21       Impact factor: 9.910

Review 5.  Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis.

Authors:  Pouria Heydarpour; Shayan Khoshkish; Shabnam Abtahi; Maziar Moradi-Lakeh; Mohammad Ali Sahraian
Journal:  Neuroepidemiology       Date:  2015-06-16       Impact factor: 3.282

6.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

7.  Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis.

Authors:  Sean J Pittock; Vanda A Lennon; Nandini Bakshi; Ling Shen; Andrew McKeon; Hong Quach; Farren B S Briggs; Allan L Bernstein; Catherine A Schaefer; Lisa F Barcellos
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

8.  International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Authors:  Dean M Wingerchuk; Brenda Banwell; Jeffrey L Bennett; Philippe Cabre; William Carroll; Tanuja Chitnis; Jérôme de Seze; Kazuo Fujihara; Benjamin Greenberg; Anu Jacob; Sven Jarius; Marco Lana-Peixoto; Michael Levy; Jack H Simon; Silvia Tenembaum; Anthony L Traboulsee; Patrick Waters; Kay E Wellik; Brian G Weinshenker
Journal:  Neurology       Date:  2015-06-19       Impact factor: 9.910

Review 9.  Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.

Authors:  Masoud Etemadifar; Zahra Nasr; Behrang Khalili; Maryam Taherioun; Reza Vosoughi
Journal:  Mult Scler Int       Date:  2015-04-20

10.  Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75.

Authors:  Markus Krumbholz; Ulrich Hofstadt-van Oy; Klemens Angstwurm; Ingo Kleiter; Sven Jarius; Friedemann Paul; Orhan Aktas; Grete Buchholz; Peter Kern; Andreas Straube; Tania Kümpfel
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

View more
  2 in total

1.  The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt.

Authors:  Nirmeen A Kishk; Walaa Abdelfattah; Nevin M Shalaby; Hatem S Shehata; Amr Hassan; Mohamed I Hegazy; Noha T Abokrysha; Doaa Abdellatif; Shereen M Shawky; Sarah S Abdo; Noha Taha; Amr M Fouad; Alaa Elmazny; Amany H Ragab
Journal:  BMC Neurol       Date:  2021-02-03       Impact factor: 2.474

2.  Cases of neuromyelitis optica spectrum disorder from the East Africa region, highlighting challenges in diagnostics and healthcare access.

Authors:  Dilraj Sokhi; Adil Suleiman; Soraiya Manji; Juzar Hooker; Peter Mativo
Journal:  eNeurologicalSci       Date:  2021-01-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.